Pharmacology · Erythropoiesis-stimulating agents (ESAs)
Epoetin alfa !
Recombinant human erythropoietin. It stimulates red cell production in the anaemia of chronic kidney disease and of chemotherapy.
Updated 2026-11-01
Also called: recombinant human erythropoietin (rHuEPO)
The figure shows human erythropoietin (the same protein as epoetin alfa) bound to the extracellular part of its receptor.
Mechanism of action
Epoetin alfa has the same amino-acid sequence as human erythropoietin. It binds erythropoietin receptors on erythroid progenitors, activates JAK2–STAT signalling and prevents their apoptosis, so more of them mature into red cells. Because red cells take time to form and live for months, haematocrit changes lag weeks behind dose changes.
- The drug binds the erythropoietin receptor in the marrow
- JAK2–STAT signalling keeps erythroid progenitors alive and dividing
- More reticulocytes, then red cells, are released
- Haemoglobin rises over weeks if iron is available
Pharmacokinetics
- Absorption
- Given intravenously or subcutaneously
- Onset and duration
- Reticulocytes rise within days; haematocrit changes lag weeks behind dose changes
Indications
- Anaemia of chronic kidney disease, on dialysis or not Chronic kidney disease →
- Anaemia caused by chemotherapy for non-curative cancer treatment
- To reduce transfusions in selected elective surgery and in HIV treatment-related anaemia
Adverse effects
Common
- Hypertension
- Headache
- Joint or muscle pain
- Nausea, vomiting
- Injection-site reactions
Contraindications
- Uncontrolled hypertension
- Pure red cell aplasia after a previous ESA
- Cancer treated with curative intent, or anaemia that can be managed by transfusion (chemotherapy setting)
Key interactions
- Iron (oral or intravenous)
- Needed for the response; iron deficiency is the commonest cause of a poor response
- Heparin during haemodialysis
- More anticoagulation may be needed as the haematocrit rises
What is monitored
- Haemoglobin regularly; the dose is reduced if it rises too fast
- Blood pressure
- Iron status (ferritin, transferrin saturation)
Administration and safety
- Intravenous (often at dialysis) or subcutaneous injection
- A biological product: kept refrigerated and not shaken
- Look-alike risk between epoetin alfa and darbepoetin alfa, which are dosed differently
Nursing care
- Check blood pressure before each dose and report rises
- Teach the signs of clots: leg swelling, chest pain, sudden weakness or trouble speaking
- In dialysis, report an access that stops working as usual
- Check that iron is replaced and that the haemoglobin target is the lowest that avoids transfusion
Pregnancy and breastfeeding
Data in pregnancy are limited; it is used when the benefit justifies it, with the same blood pressure and thrombosis precautions.
Test yourself
Think of the answer, then tap the question to see it.
Which organ normally makes erythropoietin?
The kidney.
What must be checked when the response to epoetin is poor?
Iron stores (also infection, inflammation or blood loss).
What rare complication involves antibodies against erythropoietin?
Pure red cell aplasia.
Why is it not used when chemotherapy aims at cure?
ESAs have been linked with shorter survival and tumour progression in some cancers.
Related drugs
Related conditions
← Back to the class: Erythropoiesis-stimulating agents (ESAs)
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: Epoetin Alfa, Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2019); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 45 (McGraw Hill, 2023); Farmacología básica y clínica (Katzung), 16.ª ed., cap. 33 (McGraw Hill, 2025); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.